Diego Sebastian Ojeda

Diego Sebastian Ojeda

Auto-generated profile, based on publicly available information

Diego Sebastian Ojeda

Fundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Cell Reports Medicine
Verified
Journal Article
Open access
ARAndres H. Rossi
Andres H. Rossi
DODiego S. Ojeda
Diego S. Ojeda
AVAugusto Varese
Augusto Varese
LSLautaro Sanchez
Lautaro Sanchez
MLMaria M. Gonzalez Lopez Ledesma
Maria M. Gonzalez Lopez Ledesma
AGAndrea Gamarnik
Andrea Gamarnik
Massive vaccination offers great promise for halting the global COVID-19 pandemic. However, limited supply and uneven vaccine distribution create an urgent need to optimize vaccination strategies. We evaluate SARS-CoV-2-specific antibody responses after Sputnik V vaccination of healthcare workers in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses in a cohort of naïve or previously infected volunteers. By 21 days after receiving the first dose of vaccine, 94% of naïve participants develop spike-specific IgG antibodies. A single Sputnik V dose elicits higher antibody levels and virus neutralizing capacity in previously infected individuals than in naïve ones receiving the full two-dose schedule. The high seroconversion rate after a single dose in naïve participants suggests a benefit of delaying second dose administration to increase the number of people vaccinated. The data presented provide information for guiding public health decisions in light of the current global health emergency.

14 January 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
DODiego S. Ojeda
Diego S. Ojeda
MLMaría Mora Gonzalez Lopez Ledesma
María Mora Gonzalez Lopez Ledesma
HPHoracio M. Pallarés
Horacio M. Pallarés
GNGuadalupe S. Costa Navarro
Guadalupe S. Costa Navarro
LSLautaro Sanchez
Lautaro Sanchez
AGAndrea Gamarnik
Andrea Gamarnik
We report the emergency development and application of a robust serologic test to evaluate acute and convalescent antibody responses to SARS-CoV-2 in Argentina. The assays, COVIDAR IgG and IgM, which were produced and provided for free to health authorities, private and public health institutions and nursing homes, use a combination of a trimer stabilized spike protein and the receptor binding domain (RBD) in a single enzyme-linked immunosorbent assay (ELISA) plate. Over half million tests have already been distributed to detect and quantify antibodies for multiple purposes, including assessment of immune responses in hospitalized patients and large seroprevalence studies in neighborhoods, slums and health care workers, which resulted in a powerful tool for asymptomatic detection and policy making in the country. Analysis of antibody levels and longitudinal studies of symptomatic and asymptomatic SARS-CoV-2 infections in over one thousand patient samples provided insightful information about IgM and IgG seroconversion time and kinetics, and IgM waning profiles. At least 35% of patients showed seroconversion within 7 days, and 95% within 45 days of symptoms onset, with simultaneous or close sequential IgM and IgG detection. Longitudinal studies of asymptomatic cases showed a wide range of antibody responses with median levels below those observed in symptomatic patients. Regarding convalescent plasma applications, a protocol was standardized for the assessment of end point IgG antibody titers with COVIDAR with more than 500 plasma donors. The protocol showed a positive correlation with neutralizing antibody titers, and was used for clinical trials and therapies across the country. Using this protocol, about 80% of convalescent donor plasmas were potentially suitable for therapies. Here, we demonstrate the importance of providing a robust and specific serologic assay for generating new information about antibody kinetics in infected individuals and mitigation policies to cope with pandemic needs.

1 October 2012 in Journal of Virology
Verified
Journal Article
Closed access
RRRita Reynoso
Rita Reynoso
MWMatthias Wieser
Matthias Wieser
DODiego Ojeda
Diego Ojeda
MBMaximilian Bönisch
Maximilian Bönisch
Harald KühnelHarald Kühnel
Harald Kühnel
JQJorge Quarleri
Jorge Quarleri
Monocyte-derived macrophages (MDM) are widely distributed in all tissues and organs, including the central nervous system, where they represent the main part of HIV-infected cells. In contrast to activated CD4+T lymphocytes, MDM are resistant to cytopathic effects and survive HIV infection for a long period of time. The molecular mechanisms of how HIV is able to persist in macrophages are not fully elucidated yet. In this context, we have studied the effect ofin vitroHIV-1 infection on telomerase activity (TA), telomere length, and DNA damage. Infection resulted in a significant induction of TA. This increase was directly proportional to the efficacy of HIV infection and was found in both nuclear and cytoplasmic extracts, while neither UV light-inactivated HIV nor exogenous addition of the viral protein Tat or gp120 affected TA. Furthermore, TA was not modified during monocyte-macrophage differentiation, MDM activation, or infection with vaccinia virus. HIV infection did not affect telomere length. However, HIV-infected MDM showed less DNA damage after oxidative stress than noninfected MDM, and this resistance was also increased by overexpressing telomerase alone. Taken together, our results suggest that HIV induces TA in MDM and that this induction might contribute to cellular protection against oxidative stress, which could be considered a viral strategy to make macrophages better suited as longer-lived, more resistant viral reservoirs. In the light of the clinical development of telomerase inhibitors as anticancer therapeutics, inhibition of TA in HIV-infected macrophages might also represent a novel therapeutic target against viral reservoirs.

12 March 2016 in Journal of Innate Immunity
Verified
Journal Article
Open access
PDF file
CGConstanza Giai
Constanza Giai
CGCintia D. Gonzalez
Cintia D. Gonzalez
FSFlorencia Sabbione
Florencia Sabbione
AGAilin Garofalo
Ailin Garofalo
DODiego Ojeda
Diego Ojeda
Marisa I. GómezMarisa I. Gómez
Marisa I. Gómez
Interleukin 1 (IL-1) β is a critical cytokine that orchestrates host defenses against Staphylococcus aureus and is crucial for the eradication of bacteria. The production and action of IL-1β are regulated by multiple control pathways. Among them, IL-1RII (the type II IL-1 receptor) acts as a decoy receptor and has been shown to regulate the biological effects of IL-1β. High levels of soluble IL-1RII are present in septic patients; however, the stimuli that regulate the expression and release of IL-1RII in pathological conditions are incompletely elucidated. In the present study, we demonstrated the ability of S. aureus and protein A to induce IL-1RII shedding in myeloid cells. The positive modulation of IL-1RII expression and cleavage was associated with the failure to detect IL-1β in response to S. aureus both in vitro and in vivo, suggesting that the soluble form of the receptor could be masking the availability of IL-1β. The absence of detectable IL-1β was associated with low levels of inflammatory cytokines and chemokines known to be regulated by IL-1β and with increased bacterial persistence. Modulation of decoy receptors during systemic S. aureus infection is proposed as a new strategy used by this bacterium to evade the immune response.

19 November 2013 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
DODiego Ojeda
Diego Ojeda
JLJuan José López‐Costa
Juan José López‐Costa
MSMariano Sede
Mariano Sede
ELEster María López
Ester María López
MBMaría Isabel Berria
María Isabel Berria
JQJorge Quarleri
Jorge Quarleri

17 October 2022 in Journal of Neurochemistry
Verified
Journal Article
Closed access
CCCintia Cevallos
Cintia Cevallos
DODiego S. Ojeda
Diego S. Ojeda
LSLautaro Sánchez
Lautaro Sánchez
JUJavier Urquiza
Javier Urquiza
MDM. Victoria Delpino
M. Victoria Delpino
JQJorge Quarleri
Jorge Quarleri